Once upon a time, Theranos was a promising biotech firm—raising $632 million from 2014-2015. In October 2015, everything changed when the Wall Street Journal published the first of its many exposés that revealed the company’s struggle to develop the blood-testing technology it promised. The Journal’s stories…
from Gizmodo http://ift.tt/2gqp1lu
No comments:
Post a Comment